Daiichi Sankyo Company, Limited (DSKYF)
| Previous close | 33.39 |
| Open | 33.25 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 33.09 - 33.25 |
| 52-week range | 19.45 - 34.39 |
| Volume | |
| Avg. volume | 2,332 |
| Market cap | 57.45B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 92.43 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.21 (0.69%) |
| Ex-dividend date | 30 Mar 2023 |
| 1y target est | N/A |
- Business Wire
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
TOKYO & MUNICH, January 26, 2023--ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
- Business Wire
ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer
TOKYO & MUNICH, January 04, 2023--ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer
- Business Wire
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
SANTA MONICA, Calif. & TOKYO, December 22, 2022--Kite Pharma, Inc., a Gilead Company, (hereafter, Kite) (NASDAQ: GILD) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) (TSE: 4568) today jointly announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma ( R/R LBCL): diffuse large B-cell lymphoma,
